JP2022542517A - 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 - Google Patents
血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 Download PDFInfo
- Publication number
- JP2022542517A JP2022542517A JP2022506670A JP2022506670A JP2022542517A JP 2022542517 A JP2022542517 A JP 2022542517A JP 2022506670 A JP2022506670 A JP 2022506670A JP 2022506670 A JP2022506670 A JP 2022506670A JP 2022542517 A JP2022542517 A JP 2022542517A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- inflammatory
- cytokines
- cytokine
- extracorporeal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 97
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 97
- 210000004369 blood Anatomy 0.000 title claims abstract description 56
- 239000008280 blood Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000000770 proinflammatory effect Effects 0.000 title claims abstract description 19
- 230000009467 reduction Effects 0.000 title abstract description 13
- 239000003463 adsorbent Substances 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 231100000765 toxin Toxicity 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 239000003053 toxin Substances 0.000 claims abstract description 17
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 15
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 15
- 239000000835 fiber Substances 0.000 claims abstract description 11
- 241000047703 Nonion Species 0.000 claims abstract description 9
- 244000052769 pathogen Species 0.000 claims abstract description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 64
- 239000011148 porous material Substances 0.000 claims description 32
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 29
- 230000001413 cellular effect Effects 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000002158 endotoxin Substances 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 23
- 239000012510 hollow fiber Substances 0.000 claims description 21
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- -1 aliphatic ester Chemical class 0.000 claims description 19
- 239000002594 sorbent Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 206010040047 Sepsis Diseases 0.000 claims description 13
- 206010050685 Cytokine storm Diseases 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 10
- 108010050904 Interferons Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 10
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims description 10
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 9
- 208000033626 Renal failure acute Diseases 0.000 claims description 9
- 201000011040 acute kidney failure Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 229940079322 interferon Drugs 0.000 claims description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
- 108010002386 Interleukin-3 Proteins 0.000 claims description 7
- 102000000646 Interleukin-3 Human genes 0.000 claims description 7
- 108010002335 Interleukin-9 Proteins 0.000 claims description 7
- 102000000585 Interleukin-9 Human genes 0.000 claims description 7
- 239000002095 exotoxin Substances 0.000 claims description 7
- 231100000776 exotoxin Toxicity 0.000 claims description 7
- 208000024908 graft versus host disease Diseases 0.000 claims description 7
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 102000004388 Interleukin-4 Human genes 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 102000003814 Interleukin-10 Human genes 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 4
- 244000060011 Cocos nucifera Species 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000003815 Interleukin-11 Human genes 0.000 claims description 4
- 108090000177 Interleukin-11 Proteins 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004890 Interleukin-8 Human genes 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 239000003131 biological toxin Substances 0.000 claims description 3
- 239000003610 charcoal Substances 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 230000009919 sequestration Effects 0.000 claims description 2
- 102100021592 Interleukin-7 Human genes 0.000 claims 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 1
- 102100039897 Interleukin-5 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108700012359 toxins Proteins 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000008482 dysregulation Effects 0.000 abstract description 7
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000000306 component Substances 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 8
- 230000004968 inflammatory condition Effects 0.000 description 8
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 230000016396 cytokine production Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000012261 overproduction Methods 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 3
- 102100039898 Interleukin-18 Human genes 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000026425 severe pneumonia Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000020060 Increased inflammatory response Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3475—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate with filtrate treatment agent in the same enclosure as the membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/18—Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/034—Lumen open in more than two directions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/049—Toxic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7509—General characteristics of the apparatus with filters for virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7518—General characteristics of the apparatus with filters bacterial
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2626—Absorption or adsorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/40—Adsorbents within the flow path
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
新規のシステム、装置及び方法の様々な態様は、添付の図面を参照して以下により十分に説明される。しかしながら、教示の開示は、多くの異なる形態で具体化されてもよく、本開示を通して提示される特定の構造又は機能に限定されると解釈されるべきではない。むしろ、これらの態様は、本開示が徹底的かつ完全であり、本開示の範囲を当業者に完全に伝えるように提供される。本明細書の教示に基づいて、当業者は、本開示の範囲が、本開示の任意の他の態様から独立して実施されるか、又は本開示の任意の他の態様と組み合わせられるかにかかわらず、本明細書に開示される新規のシステム、装置及び方法の任意の態様をカバーすることを意図していることを理解するはずである。例えば、システム若しくは装置が実装されてもよく、又は方法が、本明細書に記載の態様のうちの任意の1つ又はそれ以上を使用して実践されてもよい。加えて、本開示の範囲は、本明細書に記載の本開示の様々な態様に加えて、又はそれ以外の他の構造、機能性、又は構造及び機能性を使用して実践されるそのようなシステム、装置又は方法をカバーすることを意図している。本明細書に開示されたあらゆる態様は、特許請求の範囲の1つ又はそれ以上の要素に記載され得ることを理解されたい。好ましい態様のいくつかの利益及び利点が言及されているが、本開示の範囲は、特定の利益、使用又は目的に限定されることを意図するものではない。詳細な説明及び図面は、限定ではなく本開示の単なる例示であり、本開示の範囲は、添付の特許請求の範囲及びその均等物によって定義される。
本明細書で使用される場合、サイトカインは、ペプチドとタンパク質の両方の形態で存在し得る100を超える異なる免疫調節物質のファミリーを指すと定義される。サイトカインファミリーには、ケモカイン、インターフェロン、インターロイキン、リンホカイン及び腫瘍壊死因子が含まれる。
Claims (20)
- 血液から炎症性物質を除去するための体外システムであって、
ハウジングと、
前記ハウジング内に配置された中空繊維フィルタであって、前記フィルタが、約0.5ナノメートル~6000ナノメートルの直径を有する炎症性物質の通過を可能にするサイズ及び寸法の複数の細孔を備える、フィルタと、
前記ハウジングの内側及び管腔外空間内の前記中空繊維の外側に位置決めされた少なくとも1つの吸着成分と
を備える、体外システム。 - 吸着成分は、活性炭、非イオン交換樹脂及びイオン交換樹脂からなる群から選択される、請求項1に記載の体外システム。
- 前記炎症性物質は、サイトカイン、表面結合サイトカインを有するタンパク質、カプセル化サイトカインカーゴを有する細胞小胞、表面結合サイトカインを有する細胞小胞、病原体、内毒素及び外毒素からなる群から選択される、請求項1に記載の体外システム。
- 前記複数の細孔は、0.60ミクロン未満の直径を有する前記炎症性物質が繊維壁を通過し、前記吸着成分と相互作用することを可能にする、請求項3に記載の体外システム。
- 前記複数の細孔は、0.60ミクロンを超える直径を有する血液物質が前記繊維壁を通過して前記管腔外空間内の吸着成分と相互作用するのを防止するサイズ及び寸法である、請求項1に記載の体外システム。
- 前記活性炭は、コーティングされた又はコーティングされていないヤシ殻顆粒又は合成木炭を含む、請求項2に記載の体外システム。
- 前記吸着剤は、少なくとも1つのイオン交換樹脂又は非イオン交換樹脂である、請求項2に記載の体外システム。
- 前記少なくとも1つの非イオン交換樹脂は、非イオン性脂肪族エステル樹脂、非イオン性ポリスチレンジビニルベンゼン樹脂及び他の非生物吸着性樹脂からなる群から選択される、請求項2に記載の体外システム。
- 前記非イオン性脂肪族エステル樹脂の少なくとも1つは、約500m2/gの平均表面積、約300~600オングストロームの平均細孔サイズ及び560ミクロンの平均粒径を有する、請求項8に記載の体外システム。
- 前記非イオン性ポリスチレンジビニルベンゼン樹脂の少なくとも1つは、約700m2/gの平均表面積、300オングストロームの平均細孔サイズ及び約35ミクロン~約120ミクロンの平均粒径を有する、請求項8に記載の体外システム。
- 前記非イオン性ポリスチレンジビニルベンゼン樹脂の少なくとも1つは、約600m2/gの平均表面積、100~400オングストロームの平均細孔サイズ及び約300ミクロン~約500ミクロンの平均粒径を有する、請求項8に記載の体外システム。
- 前記活性炭は、100オングストローム未満のミクロ細孔領域、100~1,000オングストロームのメソ細孔領域及び1,000オングストロームを超えるマクロ細孔領域の細孔サイズ分布を有する、請求項2に記載の体外システム。
- 疾患又は障害の処置を必要とする個体において疾患又は障害を処置するための方法であって、
体外吸着毒素除去デバイスを提供するステップであって、前記デバイスが、
ハウジング、
200~6000オングストロームのサイズの複数の細孔を有する中空繊維プラズマフィルタ、並びに
前記ハウジングの内側及び管腔外空間内の前記繊維の外側に位置決めされた吸着剤
を有する、ステップと、
前記吸着毒素除去デバイスを通して疾患又は障害の処置を必要とする個体の血漿を濾過するステップであって、前記濾過により、直径が0.60ミクロン未満の炎症原因物質を前記細孔に通過させる、ステップと、
前記炎症原因物質を前記吸着剤と接触させるステップであって、前記炎症原因物質が、前記吸着剤に結合する、ステップと、
前記吸着剤中に前記炎症原因物質を捕捉するステップと
を含む、方法。 - 前記炎症原因物質の前記捕捉は、前記物質が再循環に入るのを防止する、請求項13に記載の方法。
- 前記炎症性物質は、IL-1、TNF-a、IL-11、IL-8、G-CSF及びGM-CSF、IL-3、IL-5、IL-7、IL-9及びトランスフォーミング増殖因子-b(TGF-b)からなる群から選択される炎症促進性サイトカインである、請求項13に記載の方法。
- 前記炎症性物質は、IL-1、IL-2、IL-3、IL-4、IL-6、IL-7、IL-9、IL-10、IL-12、IL-13、インターフェロン(IFN)、IFN-g誘導因子(IGIF)、TGF-b並びにTNF-α及び-bからなる群から選択される細胞性炎症に寄与する物質である、請求項13に記載の方法。
- 前記疾患又は障害は、サイトカインストーム症候群(CSS)、ウイルス誘発性サイトカインストーム、細菌誘発性サイトカインストーム、急性呼吸窮迫症候群(ARDS)、サイトカイン放出症候群(CRS)、移植片対宿主病(GVHD)、敗血症、全身性炎症反応症候群(SIRS)、肝性脳症、急性腎障害(AKI)及び肺炎からなる群から選択される、請求項13に記載の方法。
- 前記炎症性物質は、生物学的毒素である、請求項13に記載の方法。
- 前記毒素は、細菌内毒素又は外毒素である、請求項18に記載の方法。
- 疾患又は障害の処置を必要とする個体の血液から循環サイトカイン、細胞小胞、サイトカイン凝集体及び内毒素を同時に除去する方法であって、
カテーテルを用いて体外ラインを個体の循環系にアクセスするステップと、
請求項1に記載の体外システムを提供するステップであって、前記システムは、入口ポート及び出口ポートを有する、ステップと、
前記ラインを前記入口ポートに接続するステップと、
第2の体外ラインを前記出口ポートに取り付けるステップと、
ポンプを用いて前記体外システムを通る血液の流れを制御するステップと、
前記体外システムの中空繊維を通して前記血液を濾過するステップであって、前記濾過により、前記循環サイトカイン、細胞小胞、サイトカイン凝集体及び内毒素が前記細孔を通過して前記管腔外空間に入る、ステップと、
前記濾過された循環サイトカイン、細胞小胞、サイトカイン凝集体及び内毒素を前記吸着剤と接触させるステップであって、前記吸着剤が、前記サイトカイン、細胞小胞、サイトカイン凝集体及び内毒素を捕捉する、ステップと
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962881740P | 2019-08-01 | 2019-08-01 | |
US62/881,740 | 2019-08-01 | ||
PCT/US2020/044223 WO2021022023A1 (en) | 2019-08-01 | 2020-07-30 | Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022542517A true JP2022542517A (ja) | 2022-10-04 |
Family
ID=72088376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022506670A Pending JP2022542517A (ja) | 2019-08-01 | 2020-07-30 | 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210030942A1 (ja) |
EP (1) | EP4007618A1 (ja) |
JP (1) | JP2022542517A (ja) |
CA (1) | CA3148773A1 (ja) |
WO (1) | WO2021022023A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220339337A1 (en) * | 2021-04-21 | 2022-10-27 | Sigyn Therapeutics, Inc. | Extra-lumen adsorption of viral pathogens from blood |
US20230201439A1 (en) | 2021-12-27 | 2023-06-29 | Santersus Ag | Method and device for removal of circulating cell free dna |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51116096A (en) * | 1975-03-17 | 1976-10-13 | Takeda Chemical Industries Ltd | Blood processor |
JP2016501576A (ja) * | 2012-11-26 | 2016-01-21 | ガンブロ ルンディア アクチエボラグGambro Lundia AB | 肝臓補助システム |
WO2018046461A1 (en) * | 2016-09-06 | 2018-03-15 | Gambro Lundia Ab | Liver support system |
WO2018183072A1 (en) * | 2017-03-27 | 2018-10-04 | Cytosorbents Corporation | Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5211850A (en) * | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
US20020146413A1 (en) * | 2001-04-10 | 2002-10-10 | James Brady | System for treating patient with bacterial infections |
US8329388B2 (en) * | 1997-07-30 | 2012-12-11 | Cytosorbents, Inc. | Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood |
US20020197252A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
US6733827B2 (en) * | 2001-04-11 | 2004-05-11 | The Procter & Gamble Co. | Processes for manufacturing particles coated with activated lignosulfonate |
JPWO2003055545A1 (ja) * | 2001-12-25 | 2005-04-28 | 株式会社カネカ | サイトカインの吸着材、吸着除去方法および吸着除去装置 |
DE10258944A1 (de) * | 2002-12-17 | 2004-07-01 | B. Braun Medizintechnologie Gmbh | Vorrichtung zur Entfernung von bakteriellen Lipopolysacchariden oder/und Lipoteichonsäuren aus proteinhaltigen Flüssigkeiten sowie deren Verwendung zur Behandlung von Sepsis |
US8038638B2 (en) * | 2004-02-23 | 2011-10-18 | Hemolife Medical, Inc. | Plasma detoxification and volume control system and methods of use |
ES2626754T3 (es) * | 2012-11-26 | 2017-07-25 | Gambro Lundia Ab | Dispositivo de adsorción que combina perlas y membranas de fibra hueca |
CN104902941B (zh) * | 2013-02-12 | 2017-05-03 | 东丽株式会社 | 血液净化柱 |
EP3173145B1 (en) * | 2014-07-22 | 2022-09-07 | Asahi Kasei Medical Co., Ltd. | Adsorbent for removing histone and purification device for liquid derived from living organism |
GB201512468D0 (en) * | 2015-07-16 | 2015-08-19 | C Tex Ltd And University Of Brighton | Shaped nanoporous bodies |
KR102624853B1 (ko) * | 2015-07-30 | 2024-01-12 | 나가세케무텍쿠스가부시키가이샤 | 내독소 흡착제 |
ITUB20160013A1 (it) * | 2016-01-27 | 2017-07-27 | Bellco Srl | Filtro per la depurazione del sangue. |
EP3422943A4 (en) * | 2016-03-02 | 2019-10-16 | ExThera Medical Corporation | METHOD OF TREATING DRUG ENTRIES |
WO2017205720A1 (en) * | 2016-05-26 | 2017-11-30 | Drexel University | Open surface graphitic materials for adsorption of cytokines from blood |
JP7031577B2 (ja) * | 2017-04-04 | 2022-03-08 | 東レ株式会社 | 多孔質繊維および吸着カラム |
EP3658276A1 (en) * | 2017-07-26 | 2020-06-03 | SABIC Global Technologies B.V. | Composite sorbent, devices, and methods |
WO2019084111A1 (en) * | 2017-10-24 | 2019-05-02 | DD Innovations Lab, LLC | APPARATUS AND METHODS FOR REMOVING TOXINS FROM BLOOD BY PLASMASPHERESIS |
AU2018372198A1 (en) * | 2017-11-22 | 2020-06-11 | Hdl Therapeutics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
MX2020012381A (es) * | 2018-07-31 | 2021-02-09 | Toray Industries | Portador para adsorber materia organica. |
-
2020
- 2020-07-30 CA CA3148773A patent/CA3148773A1/en active Pending
- 2020-07-30 US US16/943,436 patent/US20210030942A1/en active Pending
- 2020-07-30 EP EP20757445.0A patent/EP4007618A1/en active Pending
- 2020-07-30 JP JP2022506670A patent/JP2022542517A/ja active Pending
- 2020-07-30 WO PCT/US2020/044223 patent/WO2021022023A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51116096A (en) * | 1975-03-17 | 1976-10-13 | Takeda Chemical Industries Ltd | Blood processor |
JP2016501576A (ja) * | 2012-11-26 | 2016-01-21 | ガンブロ ルンディア アクチエボラグGambro Lundia AB | 肝臓補助システム |
WO2018046461A1 (en) * | 2016-09-06 | 2018-03-15 | Gambro Lundia Ab | Liver support system |
WO2018183072A1 (en) * | 2017-03-27 | 2018-10-04 | Cytosorbents Corporation | Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in combination |
Also Published As
Publication number | Publication date |
---|---|
CA3148773A1 (en) | 2021-02-04 |
EP4007618A1 (en) | 2022-06-08 |
WO2021022023A1 (en) | 2021-02-04 |
US20210030942A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8038638B2 (en) | Plasma detoxification and volume control system and methods of use | |
US8771513B2 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
Winchester et al. | Sorbents in acute renal failure and the systemic inflammatory response syndrome | |
CN101657224B (zh) | 用于净化血液的组件 | |
WO2006002151A1 (en) | Plasma detoxification and volume control system and methods of use | |
JP2022542517A (ja) | 血液中の炎症促進性サイトカインの広範囲にわたる減少のためのデバイス、システム及び方法 | |
Linden et al. | Extracorporeal blood purification in burns: a review | |
US9265875B2 (en) | Methods for treating blood composition and function disorders wherein a patient's blood plasma is extracorporeally contacted with donor blood or modified donor blood | |
Ronco et al. | Hemoperfusion and Immunomodulation | |
Brendolan et al. | Coupled plasma filtration adsorption in the treatment of septic shock | |
WO2005099789A1 (en) | Treatment of sepsis | |
US20200222615A1 (en) | Plasma detoxification methods and systems | |
ter Beek et al. | Advanced Blood Purification Therapies | |
Damianaki et al. | Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility | |
Cantaluppic et al. | Nomenclature of Extracorporeal Blood Purification Therapies for Acute Indications: The Nomenclature Standardization Conference | |
Rogiers | Hemofiltration and Plasmapheresis | |
Fealy et al. | MARS: molecular adsorbent recirculating system | |
Schefold et al. | Extracorporeal Therapies and Immunomodulation During Sepsis | |
Gong et al. | Removal of target substances by sorbent in sepsis | |
Srisawat | Extracorporeal Blood Purification Therapy for Sepsis | |
Levine | Extracorporeal removal of plasma hemoglobin in sepsis | |
Murray et al. | Pharmacist | |
WO2015011290A1 (en) | Blood purification systems and devices with internally generated replacement fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240307 |